Form 4: Teva Pharmaceutical Director Amir Elstein Acquires 9,632 Restricted Share Units

Director Amir Elstein reports acquisition of 9,632 restricted share units in Teva Pharmaceutical Industries Ltd.

Summary

• On June 6, 2024, Amir Elstein, a director of Teva Pharmaceutical Industries Ltd., acquired 9,632 restricted share units.
• These restricted share units vest on June 6, 2025.
• Each unit represents a contingent right to receive one ordinary share or its cash value.
• The ordinary shares may be represented by American Depositary Shares (ADS), where each ADS currently represents one ordinary share.
• Following the transaction, Elstein directly owns 9,632 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of restricted share units, which is neither overtly positive nor negative.

Positives

• The acquisition of restricted share units by a director may signal confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of restricted share units in the future suggests an incentive for continued service and performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders, allowing investors to assess management's alignment with shareholder interests.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, ensuring transparency and compliance with SEC regulations.
• The vesting schedule of one year for restricted share units is a fairly common practice in the pharmaceutical industry for executive compensation.

Stakeholder Impact

• Shareholders may view the acquisition of restricted share units by a director as a positive sign, indicating confidence in the company's future performance.

Key Dates